プロスタグランジンアナログの世界市場

プロスタグランジンアナログの世界市場は2030年までに50億米ドルに到達

2024年に39億米ドルと推定されるプロスタグランジンアナログの世界市場は、2024～2030年の分析期間においてCAGR 4.4%で成長し、2030年には50億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるラタノプロスト医薬品は、CAGR 3.6%を記録し、分析期間終了時には20億米ドルに達すると予測されます。ビマトプロスト薬セグメントの成長率は、分析期間中CAGR 4.9％と推定されます。

米国市場は11億米ドルと推定、中国はCAGR6.8％で成長予測

米国のプロスタグランジンアナログ市場は2024年に11億米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを6.8%として、2030年までに9億7,210万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.1%と4.4%と予測されています。欧州では、ドイツがCAGR 2.8%で成長すると予測されています。

世界のプロスタグランジンアナログ市場- 主要動向と促進要因のまとめ

なぜプロスタグランジンアナログは薬理学的に価値ある治療薬と考えられているのか？

プロスタグランジンアナログ（PGA）は、内因性プロスタグランジンの生理作用を模倣または増強するように設計された合成化合物であり、炎症、血管緊張、生殖、眼圧調節を含む多様な生物学的機能に関与する脂質化合物です。これらのアナログは、その有効性、受容体選択性、制御可能な薬物動態プロファイルにより、眼科、産科、心臓血管治療、皮膚科などで広く使用されています。短命で不安定なことが多い天然のプロスタグランジンとは異なり、PGAは化学的に安定化されているため、作用時間が長く、標的への送達が可能です。

眼科への応用はプロスタグランジンアナログの使用の要となっています。ラタノプロスト、トラボプロスト、ビマトプロストなどの薬剤は緑内障や高眼圧症の第一選択薬です。房水のブドウ膜流出を増加させることにより、多くのβ遮断薬や炭酸脱水酵素阻害薬よりも効果的に眼圧を低下させる。さらに、PGAは皮膚科学では発毛促進（円形脱毛症など）、生殖医療では子宮頸管熟成や陣痛誘発のために評価されています。FP、EP、IPのプロスタノイド受容体に選択的に結合できることから、様々な治療分野において汎用性の高いツールとなっています。

PGAの市場範囲を拡大している治療領域と製品カテゴリーは？

プロスタグランジンアナログの最大の市場セグメントは眼科であり、PGAは緑内障治療において50％以上のシェアを占めています。PGAとチモロールのような他の血圧降下剤との合剤も、コンプライアンス向上のために勢いを増しています。眼科領域以外では、ジノプロストンやミソプロストールのようなPGAが産科領域で使用されており、これらは医学的な妊娠中絶、分娩後出血の管理、婦人科手術前の子宮頸管準備などに使用されています。

新たな用途としては、まつげ育毛のための局所製剤におけるビマトプロストの使用（「ラティース」の商品名で承認）、肺動脈性肺高血圧症や胃腸潰瘍などの症状に対する治験治療などがあります。眉毛や頭皮の毛包を刺激する皮膚科学的用途は、前臨床および初期臨床評価中です。さらに、プロスタグランジンアナログは、家畜の発情同期化および分娩誘発のために獣医学で使用されており、種を超えた生化学的汎用性を反映しています。

製剤戦略、ドラッグデリバリー、規制動向は市場にどのような影響を与えているか？

製剤の革新は、PGA製品の差別化とライフサイクル価値の拡大において極めて重要です。防腐剤フリーの点眼薬、眼内挿入剤、徐放性インプラントなど、点眼薬デリバリーの進歩は、患者のコンプライアンスに対応し、結膜充血や虹彩色素沈着などの副作用を最小限に抑えています。微粒化製剤やリポソーム製剤は、薬剤のバイオアベイラビリティと角膜透過性を向上させています。生殖医療では、放出制御型の膣挿入剤や経口錠剤が、その利便性と有害事象プロファイルの低減のために好まれています。

規制当局の観点からは、PGAは必須医薬品と利益率の高いブランド療法の境界をまたいでいます。妊産婦の健康と緑内障管理における役割から、WHOの必須医薬品モデルリストに含まれています。しかし、キサラタン（ラタノプロスト）のようなブロックバスター医薬品の特許切れに伴い、ジェネリック医薬品の競合が激化しています。FDAやEMAといった規制機関は、眼科用製剤や産科用製剤の品質基準を厳しく監視しています。発酵または半合成ルートから得られる生合成PGAも、GMP遵守とコスト競争力について評価中です。

世界のプロスタグランジンアナログ市場の成長を促進する要因は？

世界のプロスタグランジンアナログ市場の成長は、世界の緑内障発症率の上昇、妊産婦向け医薬品需要の増加、美容・皮膚科治療における適応外用途の拡大が牽引しています。世界人口の高齢化に伴い、開放隅角緑内障の有病率は上昇しており、特にアジア太平洋とラテンアメリカではPGA外用剤の持続的な需要を喚起しています。さらに、妊産婦死亡率削減のための公衆衛生機関による取り組みが、特に資源が限られた環境での生殖医療におけるPGAの使用を後押ししています。

もう一つの主な推進力は、製品パイプラインの多様化であり、慢性疼痛管理、腫瘍学的補助薬、肺疾患向けに新たなアナログ製剤が開発されています。眼科と産科の両方における併用療法の動向の高まりは、PGAの有用性を単剤療法の枠を超えて拡大しつつあります。一方、美容医療では、毛髪再生とまつ毛強化において、ニッチではあるが利益率の高いビジネスチャンスが生まれつつあります。インド、中国、東欧のジェネリック医薬品メーカーは、特に公的ヘルスケア環境において、費用対効果の高いPGA治療へのアクセスを拡大する上で極めて重要な役割を果たしています。

同市場の主なプレーヤーには、ファイザー、アラガン（アッヴィ）、サン・ファーマシューティカル・インダストリーズ、参天製薬、テバ・ファーマシューティカル・インダストリーズなどがあります。これらの企業は競争力を維持するため、ライフサイクルの延長戦略、新興地域への市場拡大、ドラッグデリバリーの技術向上を追求しています。臨床調査によって新規の受容体経路や合成誘導体が発見され続けていることから、プロスタグランジンアナログ市場は多様な治療分野で多面的かつ着実な成長を遂げることが期待されています。

セグメント

薬剤タイプ（ラタノプロスト製剤、ビマトプロスト製剤、トラボプロスト製剤、タフルプロスト製剤、その他の薬剤タイプ）、投与経路（局所投与、経口投与、注射剤）、用途（緑内障治療用途、陣痛誘発用途、勃起不全用途、胃保護用途、その他の用途）、流通チャネル（病院薬局、小売薬局、オンライン流通チャネル）

調査対象企業の例

• Aerie Pharmaceuticals, Inc.
• Allergan（AbbVie）
• ANVI Pharma
• Aspen Pharmacare（Aspen Biopharma）
• Bayer AG
• Cayman Chemical
• Chirogate
• Everlight Chemical
• Hikma Pharmaceuticals PLC
• Johnson Matthey
• Kyowa Hakko Pharma
• Lupin Pharmaceuticals
• Merck & Co., Inc.
• Novartis AG
• Ocular Therapeutix, Inc.
• Pfizer Inc.
• Sanofi CEPiA
• Santen Pharmaceutical Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.

AIインテグレーションズ

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Prostaglandin Analogs Market to Reach US$5.0 Billion by 2030

The global market for Prostaglandin Analogs estimated at US$3.9 Billion in the year 2024, is expected to reach US$5.0 Billion by 2030, growing at a CAGR of 4.4% over the analysis period 2024-2030. Latanoprost Drug, one of the segments analyzed in the report, is expected to record a 3.6% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in the Bimatoprost Drug segment is estimated at 4.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 6.8% CAGR

The Prostaglandin Analogs market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$972.1 Million by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.1% and 4.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.8% CAGR.

Global Prostaglandin Analogs Market - Key Trends & Drivers Summarized

Why Are Prostaglandin Analogs Considered Pharmacologically Valuable Therapeutic Agents?

Prostaglandin analogs (PGAs) are synthetic compounds designed to mimic or enhance the physiological effects of endogenous prostaglandins, which are lipid compounds involved in diverse biological functions including inflammation, vascular tone, reproduction, and intraocular pressure regulation. These analogs are widely used across ophthalmology, obstetrics, cardiovascular care, and dermatology due to their efficacy, receptor selectivity, and controllable pharmacokinetic profiles. Unlike natural prostaglandins, which are often short-lived and unstable, PGAs are chemically stabilized for longer action and targeted delivery.

Ophthalmic applications form the cornerstone of prostaglandin analog usage. Drugs such as latanoprost, travoprost, and bimatoprost are first-line treatments for glaucoma and ocular hypertension. By increasing uveoscleral outflow of aqueous humor, they reduce intraocular pressure more effectively than many beta-blockers or carbonic anhydrase inhibitors. Additionally, PGAs are being evaluated in dermatology for hair growth promotion (e.g., in alopecia areata) and in reproductive medicine for cervical ripening and labor induction. Their ability to selectively bind to FP, EP, or IP prostanoid receptors makes them versatile tools across multiple therapeutic disciplines.

Which Therapeutic Areas and Product Categories Are Expanding the Market Scope of PGAs?

The largest market segment for prostaglandin analogs is ophthalmology, with PGAs occupying over 50% share of the glaucoma treatment landscape. Fixed-dose combinations of PGAs with other hypotensive agents such as timolol are also gaining momentum for improving compliance. Beyond the eye care segment, obstetrics is a major arena for PGAs like dinoprostone and misoprostol, which are used for medical termination of pregnancy, management of postpartum hemorrhage, and cervical preparation prior to gynecological procedures.

Emerging applications include the use of bimatoprost in topical formulations for eyelash growth (approved under the brand name Latisse), and investigational therapies for conditions such as pulmonary arterial hypertension and gastrointestinal ulcers. Dermatological uses for stimulating eyebrow and scalp hair follicles are under preclinical and early clinical evaluation. Furthermore, prostaglandin analogs are used in veterinary medicine for estrus synchronization and labor induction in livestock, reflecting their biochemical versatility across species.

How Are Formulation Strategies, Drug Delivery, and Regulatory Trends Influencing the Market?

Formulation innovation is crucial in differentiating PGA products and extending lifecycle value. Advances in ocular delivery-such as preservative-free eye drops, intraocular inserts, and sustained-release implants-are addressing patient compliance and minimizing side effects like conjunctival hyperemia or iris pigmentation. Micronization and liposomal formulations are improving drug bioavailability and corneal penetration. In reproductive care, controlled-release vaginal inserts and oral tablet formulations are preferred for their convenience and reduced adverse event profiles.

From a regulatory perspective, PGAs straddle the boundary between essential medicines and high-margin branded therapies. They are included in the WHO Model List of Essential Medicines due to their role in maternal health and glaucoma management. However, generic competition has intensified following the patent expiry of blockbuster drugs like Xalatan (latanoprost). Regulatory agencies such as the FDA and EMA closely monitor quality standards in ophthalmic and obstetric formulations due to the sensitive nature of application sites. Biosynthetic PGAs derived through fermentation or semi-synthetic routes are also under evaluation for GMP compliance and cost competitiveness.

What Factors Are Driving the Growth of the Global Prostaglandin Analogs Market?

The growth in the global prostaglandin analogs market is driven by rising global incidence of glaucoma, increasing demand for maternal health pharmaceuticals, and expanding off-label applications in aesthetic and dermatologic treatments. As the global population ages, the prevalence of open-angle glaucoma is rising-especially in Asia-Pacific and Latin America-spurring sustained demand for topical PGA formulations. Moreover, initiatives by public health organizations to reduce maternal mortality are boosting the use of PGAs in reproductive care, particularly in resource-limited settings.

Another key driver is the diversification of product pipelines, with new analogs being developed for chronic pain management, oncology adjuncts, and pulmonary diseases. The growing trend of combination therapies, both in ophthalmology and obstetrics, is extending PGA utility beyond monotherapy. Meanwhile, aesthetic medicine is opening up niche but high-margin opportunities in hair restoration and eyelash enhancement. Generic manufacturers in India, China, and Eastern Europe are playing a pivotal role in expanding access to cost-effective PGA treatments, especially in public healthcare settings.

Major players in the market include Pfizer Inc., Allergan (AbbVie), Sun Pharmaceutical Industries, Santen Pharmaceutical, and Teva Pharmaceutical Industries. These companies are pursuing lifecycle extension strategies, market expansion into emerging regions, and technological improvements in drug delivery to retain competitiveness. As clinical research continues to uncover novel receptor pathways and synthetic derivatives, the prostaglandin analog market is positioned for steady, multifaceted growth across diverse therapeutic segments.

SCOPE OF STUDY:

The report analyzes the Prostaglandin Analogs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug, Other Drug Types); Administration Route (Topical Administration, Oral Administration, Injectable Administration); Application (Glaucoma Treatment Application, Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Aerie Pharmaceuticals, Inc.
• Allergan (AbbVie)
• ANVI Pharma
• Aspen Pharmacare (Aspen Biopharma)
• Bayer AG
• Cayman Chemical
• Chirogate
• Everlight Chemical
• Hikma Pharmaceuticals PLC
• Johnson Matthey
• Kyowa Hakko Pharma
• Lupin Pharmaceuticals
• Merck & Co., Inc.
• Novartis AG
• Ocular Therapeutix, Inc.
• Pfizer Inc.
• Sanofi CEPiA
• Santen Pharmaceutical Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Prostaglandin Analogs - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Glaucoma and Ocular Hypertension Drives Demand for Prostaglandin-Based Therapies
  • Expansion of Geriatric Population Throws the Spotlight on Age-Linked Ophthalmic Disorders
  • Growing Focus on First-Line Therapeutics Strengthens Business Case for Prostaglandin Analog Adoption
  • Regulatory Approvals for Long-Acting Formulations Expand Addressable Treatment Opportunities
  • Advancements in Ophthalmic Drug Delivery Systems Support Controlled-Release Therapies
  • Increased Research in Receptor-Selective Analogs Spurs Development of Targeted Therapeutics
  • Surge in Combination Therapies Accelerates Demand for Compatible Prostaglandin Derivatives
  • Collaborations With Academic Institutions Strengthen Preclinical Pipeline Maturity
  • Shift Toward Patient Adherence Enhancements Promotes Development of Once-Daily Dosage Forms
  • Expansion of Dermatology Applications, Including Alopecia Treatment, Broadens Market Potential
  • Emergence of Biosimilar Analogs Introduces Competitive Cost Dynamics Across Global Markets
  • Increased Use in Obstetric Indications Supports Formulation Diversification
  • Pharmaceutical Licensing Agreements Drive Geographic Expansion of Key Products
  • Strategies for Lifecycle Management Propel Next-Gen Analog Development
  • Clinical Trial Innovations Using AI and Digital Biomarkers Expedite Efficacy Validation
  • Rising Focus on Minimally Invasive Drug Delivery Mechanisms Enhances Treatment Acceptance
  • Regulatory Emphasis on Therapeutic Equivalence and Bioavailability Encourages Innovation
  • Penetration in Emerging Markets Boosts Volume-Driven Revenue Streams
  • Strategic Outsourcing of Manufacturing Supports Scalability and Market Agility
  • Focus on Therapeutic Class Differentiation Enhances Product Positioning in Competitive Pipelines
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Prostaglandin Analogs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Prostaglandin Analogs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Prostaglandin Analogs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Prostaglandin Analogs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Latanoprost Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Latanoprost Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Latanoprost Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Bimatoprost Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Bimatoprost Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Bimatoprost Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Travoprost Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Travoprost Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Travoprost Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Tafluprost Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Tafluprost Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Tafluprost Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Labor Induction Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Labor Induction Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Labor Induction Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Erectile Dysfunction Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Erectile Dysfunction Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Erectile Dysfunction Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Gastric Protection Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Gastric Protection Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Gastric Protection Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Glaucoma Treatment Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Glaucoma Treatment Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Glaucoma Treatment Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Topical Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Topical Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: World 16-Year Perspective for Topical Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: World 16-Year Perspective for Injectable Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Prostaglandin Analogs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 53: USA Recent Past, Current & Future Analysis for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: USA 16-Year Perspective for Prostaglandin Analogs by Drug Type - Percentage Breakdown of Value Sales for Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: USA 16-Year Perspective for Prostaglandin Analogs by Application - Percentage Breakdown of Value Sales for Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application for the Years 2014, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: USA 16-Year Perspective for Prostaglandin Analogs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 62: USA Recent Past, Current & Future Analysis for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: USA 16-Year Perspective for Prostaglandin Analogs by Administration Route - Percentage Breakdown of Value Sales for Topical Administration, Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: Canada 16-Year Perspective for Prostaglandin Analogs by Drug Type - Percentage Breakdown of Value Sales for Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: Canada 16-Year Perspective for Prostaglandin Analogs by Application - Percentage Breakdown of Value Sales for Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application for the Years 2014, 2025 & 2030
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: Canada 16-Year Perspective for Prostaglandin Analogs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 74: Canada Recent Past, Current & Future Analysis for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Canada Historic Review for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: Canada 16-Year Perspective for Prostaglandin Analogs by Administration Route - Percentage Breakdown of Value Sales for Topical Administration, Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
• JAPAN
  • Prostaglandin Analogs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Japan 16-Year Perspective for Prostaglandin Analogs by Drug Type - Percentage Breakdown of Value Sales for Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: Japan 16-Year Perspective for Prostaglandin Analogs by Application - Percentage Breakdown of Value Sales for Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application for the Years 2014, 2025 & 2030
  • TABLE 83: Japan Recent Past, Current & Future Analysis for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Japan Historic Review for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: Japan 16-Year Perspective for Prostaglandin Analogs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 86: Japan Recent Past, Current & Future Analysis for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Japan Historic Review for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: Japan 16-Year Perspective for Prostaglandin Analogs by Administration Route - Percentage Breakdown of Value Sales for Topical Administration, Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
• CHINA
  • Prostaglandin Analogs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 89: China Recent Past, Current & Future Analysis for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: China Historic Review for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: China 16-Year Perspective for Prostaglandin Analogs by Drug Type - Percentage Breakdown of Value Sales for Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 92: China Recent Past, Current & Future Analysis for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: China Historic Review for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: China 16-Year Perspective for Prostaglandin Analogs by Application - Percentage Breakdown of Value Sales for Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application for the Years 2014, 2025 & 2030
  • TABLE 95: China Recent Past, Current & Future Analysis for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: China Historic Review for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: China 16-Year Perspective for Prostaglandin Analogs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 98: China Recent Past, Current & Future Analysis for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: China Historic Review for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: China 16-Year Perspective for Prostaglandin Analogs by Administration Route - Percentage Breakdown of Value Sales for Topical Administration, Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
• EUROPE
  • Prostaglandin Analogs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Prostaglandin Analogs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Prostaglandin Analogs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Europe 16-Year Perspective for Prostaglandin Analogs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Europe 16-Year Perspective for Prostaglandin Analogs by Drug Type - Percentage Breakdown of Value Sales for Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 107: Europe Recent Past, Current & Future Analysis for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: Europe 16-Year Perspective for Prostaglandin Analogs by Application - Percentage Breakdown of Value Sales for Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application for the Years 2014, 2025 & 2030
  • TABLE 110: Europe Recent Past, Current & Future Analysis for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: Europe 16-Year Perspective for Prostaglandin Analogs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 113: Europe Recent Past, Current & Future Analysis for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Europe Historic Review for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: Europe 16-Year Perspective for Prostaglandin Analogs by Administration Route - Percentage Breakdown of Value Sales for Topical Administration, Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
• FRANCE
  • Prostaglandin Analogs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 116: France Recent Past, Current & Future Analysis for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: France Historic Review for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: France 16-Year Perspective for Prostaglandin Analogs by Drug Type - Percentage Breakdown of Value Sales for Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 119: France Recent Past, Current & Future Analysis for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: France Historic Review for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: France 16-Year Perspective for Prostaglandin Analogs by Application - Percentage Breakdown of Value Sales for Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application for the Years 2014, 2025 & 2030
  • TABLE 122: France Recent Past, Current & Future Analysis for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: France Historic Review for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: France 16-Year Perspective for Prostaglandin Analogs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 125: France Recent Past, Current & Future Analysis for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: France Historic Review for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: France 16-Year Perspective for Prostaglandin Analogs by Administration Route - Percentage Breakdown of Value Sales for Topical Administration, Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
• GERMANY
  • Prostaglandin Analogs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 128: Germany Recent Past, Current & Future Analysis for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Germany Historic Review for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: Germany 16-Year Perspective for Prostaglandin Analogs by Drug Type - Percentage Breakdown of Value Sales for Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 131: Germany Recent Past, Current & Future Analysis for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Germany Historic Review for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Germany 16-Year Perspective for Prostaglandin Analogs by Application - Percentage Breakdown of Value Sales for Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application for the Years 2014, 2025 & 2030
  • TABLE 134: Germany Recent Past, Current & Future Analysis for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Germany Historic Review for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Germany 16-Year Perspective for Prostaglandin Analogs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 137: Germany Recent Past, Current & Future Analysis for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Germany Historic Review for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Germany 16-Year Perspective for Prostaglandin Analogs by Administration Route - Percentage Breakdown of Value Sales for Topical Administration, Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 140: Italy Recent Past, Current & Future Analysis for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Italy Historic Review for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Italy 16-Year Perspective for Prostaglandin Analogs by Drug Type - Percentage Breakdown of Value Sales for Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 143: Italy Recent Past, Current & Future Analysis for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Italy Historic Review for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Italy 16-Year Perspective for Prostaglandin Analogs by Application - Percentage Breakdown of Value Sales for Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application for the Years 2014, 2025 & 2030
  • TABLE 146: Italy Recent Past, Current & Future Analysis for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Italy Historic Review for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Italy 16-Year Perspective for Prostaglandin Analogs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 149: Italy Recent Past, Current & Future Analysis for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Italy Historic Review for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Italy 16-Year Perspective for Prostaglandin Analogs by Administration Route - Percentage Breakdown of Value Sales for Topical Administration, Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Prostaglandin Analogs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 152: UK Recent Past, Current & Future Analysis for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: UK Historic Review for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: UK 16-Year Perspective for Prostaglandin Analogs by Drug Type - Percentage Breakdown of Value Sales for Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 155: UK Recent Past, Current & Future Analysis for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: UK Historic Review for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: UK 16-Year Perspective for Prostaglandin Analogs by Application - Percentage Breakdown of Value Sales for Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application for the Years 2014, 2025 & 2030
  • TABLE 158: UK Recent Past, Current & Future Analysis for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: UK Historic Review for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: UK 16-Year Perspective for Prostaglandin Analogs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 161: UK Recent Past, Current & Future Analysis for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: UK Historic Review for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: UK 16-Year Perspective for Prostaglandin Analogs by Administration Route - Percentage Breakdown of Value Sales for Topical Administration, Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 164: Spain Recent Past, Current & Future Analysis for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Spain Historic Review for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: Spain 16-Year Perspective for Prostaglandin Analogs by Drug Type - Percentage Breakdown of Value Sales for Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 167: Spain Recent Past, Current & Future Analysis for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Spain Historic Review for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: Spain 16-Year Perspective for Prostaglandin Analogs by Application - Percentage Breakdown of Value Sales for Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application for the Years 2014, 2025 & 2030
  • TABLE 170: Spain Recent Past, Current & Future Analysis for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Spain Historic Review for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: Spain 16-Year Perspective for Prostaglandin Analogs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 173: Spain Recent Past, Current & Future Analysis for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Spain Historic Review for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: Spain 16-Year Perspective for Prostaglandin Analogs by Administration Route - Percentage Breakdown of Value Sales for Topical Administration, Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 176: Russia Recent Past, Current & Future Analysis for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Russia Historic Review for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: Russia 16-Year Perspective for Prostaglandin Analogs by Drug Type - Percentage Breakdown of Value Sales for Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 179: Russia Recent Past, Current & Future Analysis for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Russia Historic Review for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: Russia 16-Year Perspective for Prostaglandin Analogs by Application - Percentage Breakdown of Value Sales for Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application for the Years 2014, 2025 & 2030
  • TABLE 182: Russia Recent Past, Current & Future Analysis for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Russia Historic Review for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: Russia 16-Year Perspective for Prostaglandin Analogs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 185: Russia Recent Past, Current & Future Analysis for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Russia Historic Review for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: Russia 16-Year Perspective for Prostaglandin Analogs by Administration Route - Percentage Breakdown of Value Sales for Topical Administration, Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Europe Historic Review for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: Rest of Europe 16-Year Perspective for Prostaglandin Analogs by Drug Type - Percentage Breakdown of Value Sales for Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Europe Historic Review for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Rest of Europe 16-Year Perspective for Prostaglandin Analogs by Application - Percentage Breakdown of Value Sales for Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application for the Years 2014, 2025 & 2030
  • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Europe Historic Review for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Rest of Europe 16-Year Perspective for Prostaglandin Analogs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Europe Historic Review for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Rest of Europe 16-Year Perspective for Prostaglandin Analogs by Administration Route - Percentage Breakdown of Value Sales for Topical Administration, Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Prostaglandin Analogs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Prostaglandin Analogs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Prostaglandin Analogs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 16-Year Perspective for Prostaglandin Analogs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 16-Year Perspective for Prostaglandin Analogs by Drug Type - Percentage Breakdown of Value Sales for Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 16-Year Perspective for Prostaglandin Analogs by Application - Percentage Breakdown of Value Sales for Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application for the Years 2014, 2025 & 2030
  • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Asia-Pacific Historic Review for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Asia-Pacific 16-Year Perspective for Prostaglandin Analogs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Asia-Pacific Historic Review for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Asia-Pacific 16-Year Perspective for Prostaglandin Analogs by Administration Route - Percentage Breakdown of Value Sales for Topical Administration, Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Prostaglandin Analogs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 215: Australia Recent Past, Current & Future Analysis for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Australia Historic Review for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: Australia 16-Year Perspective for Prostaglandin Analogs by Drug Type - Percentage Breakdown of Value Sales for Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 218: Australia Recent Past, Current & Future Analysis for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Australia Historic Review for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: Australia 16-Year Perspective for Prostaglandin Analogs by Application - Percentage Breakdown of Value Sales for Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application for the Years 2014, 2025 & 2030
  • TABLE 221: Australia Recent Past, Current & Future Analysis for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Australia Historic Review for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: Australia 16-Year Perspective for Prostaglandin Analogs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 224: Australia Recent Past, Current & Future Analysis for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Australia Historic Review for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: Australia 16-Year Perspective for Prostaglandin Analogs by Administration Route - Percentage Breakdown of Value Sales for Topical Administration, Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
• INDIA
  • Prostaglandin Analogs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 227: India Recent Past, Current & Future Analysis for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: India Historic Review for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 229: India 16-Year Perspective for Prostaglandin Analogs by Drug Type - Percentage Breakdown of Value Sales for Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 230: India Recent Past, Current & Future Analysis for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: India Historic Review for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 232: India 16-Year Perspective for Prostaglandin Analogs by Application - Percentage Breakdown of Value Sales for Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application for the Years 2014, 2025 & 2030
  • TABLE 233: India Recent Past, Current & Future Analysis for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: India Historic Review for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 235: India 16-Year Perspective for Prostaglandin Analogs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 236: India Recent Past, Current & Future Analysis for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: India Historic Review for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 238: India 16-Year Perspective for Prostaglandin Analogs by Administration Route - Percentage Breakdown of Value Sales for Topical Administration, Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 239: South Korea Recent Past, Current & Future Analysis for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: South Korea Historic Review for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 241: South Korea 16-Year Perspective for Prostaglandin Analogs by Drug Type - Percentage Breakdown of Value Sales for Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 242: South Korea Recent Past, Current & Future Analysis for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: South Korea Historic Review for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 244: South Korea 16-Year Perspective for Prostaglandin Analogs by Application - Percentage Breakdown of Value Sales for Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application for the Years 2014, 2025 & 2030
  • TABLE 245: South Korea Recent Past, Current & Future Analysis for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: South Korea Historic Review for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 247: South Korea 16-Year Perspective for Prostaglandin Analogs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 248: South Korea Recent Past, Current & Future Analysis for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: South Korea Historic Review for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 250: South Korea 16-Year Perspective for Prostaglandin Analogs by Administration Route - Percentage Breakdown of Value Sales for Topical Administration, Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Asia-Pacific Historic Review for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 253: Rest of Asia-Pacific 16-Year Perspective for Prostaglandin Analogs by Drug Type - Percentage Breakdown of Value Sales for Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Asia-Pacific Historic Review for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 256: Rest of Asia-Pacific 16-Year Perspective for Prostaglandin Analogs by Application - Percentage Breakdown of Value Sales for Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application for the Years 2014, 2025 & 2030
  • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Asia-Pacific Historic Review for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 259: Rest of Asia-Pacific 16-Year Perspective for Prostaglandin Analogs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Rest of Asia-Pacific Historic Review for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 262: Rest of Asia-Pacific 16-Year Perspective for Prostaglandin Analogs by Administration Route - Percentage Breakdown of Value Sales for Topical Administration, Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Prostaglandin Analogs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Prostaglandin Analogs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Prostaglandin Analogs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 265: Latin America 16-Year Perspective for Prostaglandin Analogs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 268: Latin America 16-Year Perspective for Prostaglandin Analogs by Drug Type - Percentage Breakdown of Value Sales for Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 271: Latin America 16-Year Perspective for Prostaglandin Analogs by Application - Percentage Breakdown of Value Sales for Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application for the Years 2014, 2025 & 2030
  • TABLE 272: Latin America Recent Past, Current & Future Analysis for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Latin America Historic Review for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 274: Latin America 16-Year Perspective for Prostaglandin Analogs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 275: Latin America Recent Past, Current & Future Analysis for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Latin America Historic Review for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 277: Latin America 16-Year Perspective for Prostaglandin Analogs by Administration Route - Percentage Breakdown of Value Sales for Topical Administration, Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 278: Argentina Recent Past, Current & Future Analysis for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Argentina Historic Review for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 280: Argentina 16-Year Perspective for Prostaglandin Analogs by Drug Type - Percentage Breakdown of Value Sales for Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 281: Argentina Recent Past, Current & Future Analysis for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Argentina Historic Review for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 283: Argentina 16-Year Perspective for Prostaglandin Analogs by Application - Percentage Breakdown of Value Sales for Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application for the Years 2014, 2025 & 2030
  • TABLE 284: Argentina Recent Past, Current & Future Analysis for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Argentina Historic Review for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 286: Argentina 16-Year Perspective for Prostaglandin Analogs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 287: Argentina Recent Past, Current & Future Analysis for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Argentina Historic Review for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 289: Argentina 16-Year Perspective for Prostaglandin Analogs by Administration Route - Percentage Breakdown of Value Sales for Topical Administration, Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 290: Brazil Recent Past, Current & Future Analysis for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Brazil Historic Review for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 292: Brazil 16-Year Perspective for Prostaglandin Analogs by Drug Type - Percentage Breakdown of Value Sales for Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 293: Brazil Recent Past, Current & Future Analysis for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Brazil Historic Review for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 295: Brazil 16-Year Perspective for Prostaglandin Analogs by Application - Percentage Breakdown of Value Sales for Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application for the Years 2014, 2025 & 2030
  • TABLE 296: Brazil Recent Past, Current & Future Analysis for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Brazil Historic Review for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 298: Brazil 16-Year Perspective for Prostaglandin Analogs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 299: Brazil Recent Past, Current & Future Analysis for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Brazil Historic Review for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 301: Brazil 16-Year Perspective for Prostaglandin Analogs by Administration Route - Percentage Breakdown of Value Sales for Topical Administration, Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 302: Mexico Recent Past, Current & Future Analysis for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Mexico Historic Review for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 304: Mexico 16-Year Perspective for Prostaglandin Analogs by Drug Type - Percentage Breakdown of Value Sales for Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 305: Mexico Recent Past, Current & Future Analysis for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Mexico Historic Review for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 307: Mexico 16-Year Perspective for Prostaglandin Analogs by Application - Percentage Breakdown of Value Sales for Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application for the Years 2014, 2025 & 2030
  • TABLE 308: Mexico Recent Past, Current & Future Analysis for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Mexico Historic Review for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 310: Mexico 16-Year Perspective for Prostaglandin Analogs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 311: Mexico Recent Past, Current & Future Analysis for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Mexico Historic Review for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 313: Mexico 16-Year Perspective for Prostaglandin Analogs by Administration Route - Percentage Breakdown of Value Sales for Topical Administration, Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Latin America Historic Review for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 316: Rest of Latin America 16-Year Perspective for Prostaglandin Analogs by Drug Type - Percentage Breakdown of Value Sales for Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Latin America Historic Review for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 319: Rest of Latin America 16-Year Perspective for Prostaglandin Analogs by Application - Percentage Breakdown of Value Sales for Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application for the Years 2014, 2025 & 2030
  • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Latin America Historic Review for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 322: Rest of Latin America 16-Year Perspective for Prostaglandin Analogs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Rest of Latin America Historic Review for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 325: Rest of Latin America 16-Year Perspective for Prostaglandin Analogs by Administration Route - Percentage Breakdown of Value Sales for Topical Administration, Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Prostaglandin Analogs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Prostaglandin Analogs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Prostaglandin Analogs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 328: Middle East 16-Year Perspective for Prostaglandin Analogs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 331: Middle East 16-Year Perspective for Prostaglandin Analogs by Drug Type - Percentage Breakdown of Value Sales for Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 334: Middle East 16-Year Perspective for Prostaglandin Analogs by Application - Percentage Breakdown of Value Sales for Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application for the Years 2014, 2025 & 2030
  • TABLE 335: Middle East Recent Past, Current & Future Analysis for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Middle East Historic Review for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 337: Middle East 16-Year Perspective for Prostaglandin Analogs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 338: Middle East Recent Past, Current & Future Analysis for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Middle East Historic Review for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 340: Middle East 16-Year Perspective for Prostaglandin Analogs by Administration Route - Percentage Breakdown of Value Sales for Topical Administration, Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 341: Iran Recent Past, Current & Future Analysis for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Iran Historic Review for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 343: Iran 16-Year Perspective for Prostaglandin Analogs by Drug Type - Percentage Breakdown of Value Sales for Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 344: Iran Recent Past, Current & Future Analysis for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Iran Historic Review for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 346: Iran 16-Year Perspective for Prostaglandin Analogs by Application - Percentage Breakdown of Value Sales for Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application for the Years 2014, 2025 & 2030
  • TABLE 347: Iran Recent Past, Current & Future Analysis for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Iran Historic Review for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 349: Iran 16-Year Perspective for Prostaglandin Analogs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 350: Iran Recent Past, Current & Future Analysis for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Iran Historic Review for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 352: Iran 16-Year Perspective for Prostaglandin Analogs by Administration Route - Percentage Breakdown of Value Sales for Topical Administration, Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 353: Israel Recent Past, Current & Future Analysis for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Israel Historic Review for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 355: Israel 16-Year Perspective for Prostaglandin Analogs by Drug Type - Percentage Breakdown of Value Sales for Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 356: Israel Recent Past, Current & Future Analysis for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Israel Historic Review for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 358: Israel 16-Year Perspective for Prostaglandin Analogs by Application - Percentage Breakdown of Value Sales for Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application for the Years 2014, 2025 & 2030
  • TABLE 359: Israel Recent Past, Current & Future Analysis for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Israel Historic Review for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 361: Israel 16-Year Perspective for Prostaglandin Analogs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 362: Israel Recent Past, Current & Future Analysis for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Israel Historic Review for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 364: Israel 16-Year Perspective for Prostaglandin Analogs by Administration Route - Percentage Breakdown of Value Sales for Topical Administration, Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Saudi Arabia Historic Review for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 367: Saudi Arabia 16-Year Perspective for Prostaglandin Analogs by Drug Type - Percentage Breakdown of Value Sales for Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Saudi Arabia Historic Review for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 370: Saudi Arabia 16-Year Perspective for Prostaglandin Analogs by Application - Percentage Breakdown of Value Sales for Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application for the Years 2014, 2025 & 2030
  • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Saudi Arabia Historic Review for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 373: Saudi Arabia 16-Year Perspective for Prostaglandin Analogs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Saudi Arabia Historic Review for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 376: Saudi Arabia 16-Year Perspective for Prostaglandin Analogs by Administration Route - Percentage Breakdown of Value Sales for Topical Administration, Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 377: UAE Recent Past, Current & Future Analysis for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: UAE Historic Review for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 379: UAE 16-Year Perspective for Prostaglandin Analogs by Drug Type - Percentage Breakdown of Value Sales for Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 380: UAE Recent Past, Current & Future Analysis for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: UAE Historic Review for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 382: UAE 16-Year Perspective for Prostaglandin Analogs by Application - Percentage Breakdown of Value Sales for Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application for the Years 2014, 2025 & 2030
  • TABLE 383: UAE Recent Past, Current & Future Analysis for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: UAE Historic Review for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 385: UAE 16-Year Perspective for Prostaglandin Analogs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 386: UAE Recent Past, Current & Future Analysis for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: UAE Historic Review for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 388: UAE 16-Year Perspective for Prostaglandin Analogs by Administration Route - Percentage Breakdown of Value Sales for Topical Administration, Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Rest of Middle East Historic Review for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 391: Rest of Middle East 16-Year Perspective for Prostaglandin Analogs by Drug Type - Percentage Breakdown of Value Sales for Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Middle East Historic Review for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 394: Rest of Middle East 16-Year Perspective for Prostaglandin Analogs by Application - Percentage Breakdown of Value Sales for Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application for the Years 2014, 2025 & 2030
  • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Middle East Historic Review for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 397: Rest of Middle East 16-Year Perspective for Prostaglandin Analogs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Rest of Middle East Historic Review for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 400: Rest of Middle East 16-Year Perspective for Prostaglandin Analogs by Administration Route - Percentage Breakdown of Value Sales for Topical Administration, Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
• AFRICA
  • Prostaglandin Analogs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 401: Africa Recent Past, Current & Future Analysis for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Africa Historic Review for Prostaglandin Analogs by Drug Type - Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 403: Africa 16-Year Perspective for Prostaglandin Analogs by Drug Type - Percentage Breakdown of Value Sales for Latanoprost Drug, Bimatoprost Drug, Travoprost Drug, Tafluprost Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 404: Africa Recent Past, Current & Future Analysis for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Africa Historic Review for Prostaglandin Analogs by Application - Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 406: Africa 16-Year Perspective for Prostaglandin Analogs by Application - Percentage Breakdown of Value Sales for Labor Induction Application, Erectile Dysfunction Application, Gastric Protection Application, Other Applications and Glaucoma Treatment Application for the Years 2014, 2025 & 2030
  • TABLE 407: Africa Recent Past, Current & Future Analysis for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Africa Historic Review for Prostaglandin Analogs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 409: Africa 16-Year Perspective for Prostaglandin Analogs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 410: Africa Recent Past, Current & Future Analysis for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Africa Historic Review for Prostaglandin Analogs by Administration Route - Topical Administration, Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 412: Africa 16-Year Perspective for Prostaglandin Analogs by Administration Route - Percentage Breakdown of Value Sales for Topical Administration, Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030

IV. COMPETITION